Your browser is no longer supported. Please, upgrade your browser.
Settings
BVXV BiondVax Pharmaceuticals Ltd. daily Stock Chart
BVXV [NASD]
BiondVax Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-1.56 Insider Own- Shs Outstand162.48M Perf Week10.81%
Market Cap1.67B Forward P/E- EPS next Y-0.03 Insider Trans- Shs Float3.15M Perf Month16.48%
Income- PEG- EPS next Q- Inst Own- Short Float0.64% Perf Quarter63.22%
Sales- P/S- EPS this Y96.20% Inst Trans- Short Ratio0.70 Perf Half Y124.78%
Book/sh2.08 P/B4.93 EPS next Y0.00% ROA- Target Price15.00 Perf Year179.29%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.04 - 10.72 Perf YTD205.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.38% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low237.17% ATR0.62
Employees17 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)70.46 Volatility9.41% 5.79%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.52 Prev Close10.42
ShortableYes LT Debt/Eq- EarningsAug 29 BMO Payout- Avg Volume29.03K Price10.25
Recom2.00 SMA2018.56% SMA5026.20% SMA20082.14% Volume44,261 Change-1.63%
Jul-20-17 06:30AM  BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine PR Newswire
Jul-18-17 07:30AM  BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine PR Newswire
Jul-06-17 01:00PM  BVXV: Secures $22 Million Loan Agreement with European Investment Bank Zacks Small Cap Research
Jun-28-17 04:01PM  BiondVax's CEO Provides First Half 2017 General Corporate Update PR Newswire
Jun-19-17 07:00AM  European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative PR Newswire +10.64%
Jun-12-17 08:15AM  Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials Accesswire
Jun-02-17 01:00PM  BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon Zacks Small Cap Research
May-30-17 07:00AM  BiondVax Announces First Quarter 2017 Financial Results and Update PR Newswire
May-08-17 03:00PM  BVXV: Awarded Grant to Build Commercial Scale Facility for Production of M-001 Zacks Small Cap Research
Apr-28-17 08:00AM  BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update PR Newswire
Mar-30-17 11:59AM  BiondVax Gets Approval to Build Plant in Israel Investopedia +9.52%
11:59AM  BiondVax Gets Approval to Build Plant in Israel at Investopedia
02:00AM  BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine PR Newswire
Mar-13-17 09:30AM  BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal PR Newswire
Jan-20-17 11:30AM  BVXV: New Publication Shows M-001 Incites Immune Protection Against Current and Future Influenza Strains Zacks Small Cap Research
Jan-12-17 07:00AM  Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist PR Newswire +5.60%
Jan-02-17 03:00AM  BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd. PR Newswire
Dec-01-16 11:00AM  BVXV: Phase 2b Trial Shows M-001 is Safe and Well Tolerated Zacks Small Cap Research
Nov-29-16 07:30AM  BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated PR Newswire
Nov-28-16 08:08AM  BiondVax Announces Third Quarter 2016 Financial Results and Update PR Newswire
Nov-22-16 07:00AM  Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVaxs Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains PR Newswire
Biondvax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company offers M-001, a synthetic peptide-based protein, which is in Phase 2 clinical development stage targeting seasonal and pandemic strains of the influenza virus. Biondvax Pharmaceuticals Ltd. was founded in 2003 and is based in Ness Ziona, Israel.